In this Product Explainer, Gastroenterologist Prof Finlay Macrae AO explains the common challenges when following a strict gluten free diet and the role of enzyme supplementation with GluteGuard.
The SURMOUNT-5 trial has provided definitive evidence that tirzepatide is superior to semaglutide for obesity treatment, achieving an additional 6.5% body weight reduction and nearly doubling the proportion of patients who lose 25% or more of their body weight.
Dr Ted Wu discussed the opportunities and challenges that future research into cardiovascular outcomes in patients with type 2 diabetes are likely to encounter.
This presentation discuss the risk of nutritional deficits and loss of muscle mass associated with the use of GLP-1 receptor agonists and recommendations on how to reduce these risks.
New research shows how blood sugar problems affect brain health and vice versa. Here are ten evidence-based insights into how the two conditions are related.
Dr Melissa Beitner discusses how to approach obesity as a chronic disease, providing clear insights on assessment, treatment options, and the GP’s role in long-term patient support.